Back to Search
Start Over
Effectiveness and cost-effectiveness of trastuzumab emtansine in women with HER2-positive locally advanced or metastatic breast cancer: A systematic review and meta-analysis
- Source :
- Journal of cancer research and therapeutics. 18(4)
- Publication Year :
- 2022
-
Abstract
- Trastuzumab emtansine (T-DM1) is a human epidermal growth factor receptor-2 targeted antibody-drug conjugate that contains a monoclonal antibody, trastuzumab, covalently linked to DM1, a small molecule cytotoxin.We conducted a systematic review and meta-analysis of published trials to examine the efficacy and safety of T-DM1 for patients with HER2-positive metastatic breast cancer. In addition, we systematically reviewed existing economic evaluations of T-DM1. An electronic literature search of online databases (Medline, CENTRAL, and Embase) was performed. Randomized controlled trials that compared T-DM1 with other active treatment agents were eligible for inclusion. In addition, studies that involved T-DM1 as one of the treatment comparators in an economic evaluation were included. Four trials with a total of 2462 participants were included in this meta-analysis.Pooled results showed T-DM1 substantially improved overall survival (hazard ratio [HR], 0.75; 95% confidence interval [CI], 0.67-0.85; IT-DM1 is effective for the treatment of patients with HER2-positive metastatic breast cancer, and it demonstrates a tolerable safety profile compared with other active controls. Little evidence was available regarding the cost-effectiveness of T-DM1 so no conclusions can be drawn.
- Subjects :
- Immunoconjugates
Cytotoxins
Receptor, ErbB-2
Cost-Benefit Analysis
Breast Neoplasms
General Medicine
Trastuzumab
Ado-Trastuzumab Emtansine
Antibodies, Monoclonal, Humanized
Disease-Free Survival
Oncology
Antineoplastic Combined Chemotherapy Protocols
Humans
Radiology, Nuclear Medicine and imaging
Female
Maytansine
Subjects
Details
- ISSN :
- 19984138
- Volume :
- 18
- Issue :
- 4
- Database :
- OpenAIRE
- Journal :
- Journal of cancer research and therapeutics
- Accession number :
- edsair.doi.dedup.....8fa60855251f120f64c3322fe1972e45